CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The project aims to enhance treatment for refractory neuroblastoma by combining ferroptotic drugs with natural killer cell therapy. This innovative approach seeks to overcome the challenges posed by the tumor microenvironment and improve patient outcomes through predictive modeling.
Neuroblastoma (NB), a rare paediatric solid tumour, accounts for 15% of childhood cancer deaths.
Immunotherapy has improved the survival for haematological malignancies, but solid tumours remain a challenge.
The high heterogeneity, low mutational load, and strong immunosuppressive tumour microenvironment (i-TME) have hindered the success of immunotherapy in NB.
Recently, natural killer (NK) cells have stood as a promising immunotherapeutic tool, as they don’t depend on specific mutations.
Still,…
FUNDACION PARA LA INVESTIGACION BIOMEDICA DEL HOSPITAL UNIVERSIATRIO LA PAZ
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Spain, Ciudad Real
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
